Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FSCE4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $67,050
Award facts
- Contract value 100% obligated
- $67,050.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $67,050.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for 68 mg Nexplanon implants on January 21, 2026, with an ultimate completion date of February 11, 2026. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, and the awardee for this delivery order. The contract includes no set-aside designation, indicating the award was made through full and open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion federal acquisition strategy designed to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
The Nexplanon implant delivery supports the Defense Logistics Agency's medical supply chain operations, which serve military healthcare facilities globally. DMS Pharmaceutical Group has demonstrated consistent performance across the PPV-G GEN V contract, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The indefinite delivery contract encompasses a 30-month base period with three optional 30-month extension periods, positioning DMS Pharmaceutical Group as a critical supplier for Department of Defense pharmaceutical and medical consumable requirements. The company's established portfolio includes specialty pharmaceuticals, biologics, vaccines, and contraceptive devices, enabling it to fulfill diverse medical supply needs across military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FSCE4?
SPE2DR26FSCE4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FSCE4 worth?
The government has obligated $67,050 on SPE2DR26FSCE4.
Is contract SPE2DR26FSCE4 an order under another contract?
Yes. SPE2DR26FSCE4 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCE4 competed?
The extent of competition for SPE2DR26FSCE4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award